The broad-spectrum anti-bacterial agent belongs to the fourth-generation fluoroquinolone antibiotics.
Where the Principles for Management of Pneumonia in Patients With COVID-19 are relevant to bacterial pathogens in patients with pneumonia
Therefore, Moxifloxacin Constitutes a first-line therapeutic agent for the management of severe community-acquired pneumonia and is characterized by Immunomodulatory Activities :
• Down-regulation of the syntheses of pro-inflammatory cytokines
• Up-regulation of the syntheses of hematopoietic growth factor
Available forms: tablet oral form and IV infusion form
dose: once daily for 10 days in Community-Acquired Pneumonia CAP.

Levofloxacin, the broad spectrum anti-bacterial agent which belongs to fluoroquinolone antibiotics.

Dose: once daily Tablet for 7-14 days in cases of Community Acquired Pneumonia CAP.